APA

Lai T. Y. Y., Luk F. O. J., Lee G. K. Y. & Lam D. S. C. (20120928). Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. : Eye (London, England).

Chicago

Lai T Y Y, Luk F O J, Lee G K Y and Lam D S C. 20120928. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. : Eye (London, England).

Harvard

Lai T. Y. Y., Luk F. O. J., Lee G. K. Y. and Lam D. S. C. (20120928). Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. : Eye (London, England).

MLA

Lai T Y Y, Luk F O J, Lee G K Y and Lam D S C. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. : Eye (London, England). 20120928.